Loading data for OGN — first visit, this takes a few seconds.
Organon & Co. (OGN)
NYSE: OGN
· Real-Time Price · USD
13.75
+0.00 (0.00%)
At close: Aug 24, 2026, 8:00 PM
13.75
+0.00%
After-hours: 6:16 PM
The price, the headline numbers and the latest news, in one place.
Organon & Co. (OGN) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 13.36 |
| Market Cap | 3.61B |
| Revenue (ttm) | 6.13B |
| Net Income (ttm) | 209M |
| 1.52 | |
| 0.78 | |
| 17.63 | |
| 3.8 | |
| P/B (ttm) | 3.59 |
| P/S (ttm) | 0.59 |
| Earnings Date | Nov 9, 2026 |
| Ask | 13.8 |
| Volume | 4,583,387 |
| Avg. Volume (20D) | 2,621,537 |
| Open | 13.73 |
| Previous Close | 13.75 |
| Day's Range | 13.72 - 13.76 |
| 52-Week Range | 5.69 - 13.76 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.08 (0.58%) |
| Ex-Dividend Date | Aug 14, 2026 |
About OGN
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; C...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 14, 2021
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Website https://www.organon.com
Financial Performance
In 2025, Organon &'s revenue was 6.22B, a decrease of -2.92% compared to the previous year's 6.4B. Earnings were 187M, a decrease of -78.36%.
Financial StatementsEarnings Surprise
Organon & has released their quarterly earnings on Jul 31, 2026:
- Revenue of $1.56B misses estimates by $0, with -2.26% YoY decline.
- EPS of 0.85 misses estimates by -0.22, with -15.00% YoY decline.
Organon & Co. is scheduled to release its earnings on Nov 9, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2